Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03G. D’Addario, Daniel Betticher, L.M. Jost et al.|Annals of Oncology|2007Cited by 43
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)Christoph Rochlitz, Khalil Zaman, Thomas Ruhstaller et al.|Annals of Oncology|2010Cited by 26
Quality of life (QoL) in SAKK 19/03: A multicenter phase II study of first-line gefitinib followed by chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Swiss Group for Clinical Cancer Research (SAKK)G. D’Addario, Daniel Betticher, Florian Strasser et al.|Journal of Clinical Oncology|2006Cited by 0